Clinical Trial Detail

NCT ID NCT02651610
Title Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Peregrine Pharmaceuticals
Indications

Her2-receptor negative breast cancer

Therapies

Bavituximab

Paclitaxel

Age Groups: adult

Additional content available in CKB BOOST